Evidence map›Paper›PMID 29302237›Full record

ArticleReviews in urology2017

Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results.

Stephen M Zappala, Peter T Scardino, David Okrongly, Vincent Linder, Yan Dong

Open access · greenAbstract read
In one paragraph

Article in Reviews in urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  7. Review
  8. Review
  9. Prostate cancer biomarkers: from early diagnosis to precision treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer.International journal of molecular sciences · 2023
    Article
  17. Biomarkers of Aggressive Prostate Cancer at Diagnosis.International journal of molecular sciences · 2023
    Review
  18. Commentary on Novitas LCD.Bladder cancer (Amsterdam, Netherlands) · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stephen M ZappalaTufts University School of MedicineBoston, MA.
Peter T ScardinoMemorial Sloan Kettering Cancer CenterNew York, NY.
David OkronglyOPKO DiagnosticsMiami, FL.
Vincent LinderOPKO DiagnosticsWoburn, MA.
Yan DongOPKO DiagnosticsWoburn, MA.
Cornell University · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 4Kscore

Indexed as

4Kscore TestBiomarkersBiopsyEarly detectionHigh-grade prostate cancer

Identifiers

PMID29302237
PMCPMC5737341
OpenAlexW2980530742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.